PFIZER-E Drug Patent Profile
✉ Email this page to a colleague
When do Pfizer-e patents expire, and when can generic versions of Pfizer-e launch?
Pfizer-e is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in PFIZER-E is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PFIZER-E?
- What are the global sales for PFIZER-E?
- What is Average Wholesale Price for PFIZER-E?
Summary for PFIZER-E
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Clinical Trials: | 313 |
| Patent Applications: | 1 |
| DailyMed Link: | PFIZER-E at DailyMed |
Recent Clinical Trials for PFIZER-E
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Rouen | Phase 3 |
| Dana-Farber Cancer Institute | Phase 2 |
| Prostate Cancer Foundation | Phase 2 |
US Patents and Regulatory Information for PFIZER-E
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | PFIZER-E | erythromycin stearate | TABLET;ORAL | 061791-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | PFIZER-E | erythromycin stearate | TABLET;ORAL | 061791-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
